Kidney Restore by Healthy Kidney — Ingredients, Evidence & Safety

Product Label

📄 Open Full PDF View on NIH DSLD →

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 40mg is 1.1× the Tolerable Upper Intake Level (35mg)

Label Data

1 Capsule(s) Serving Size

60 Servings

Other Combinations Product Type

40% Evidence Coverage

Supplement Facts — Evidence Check

Niacin

40 mg (250% DV)

⚠️ Exceeds Tolerable Upper Intake Level by 1.1× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)

RDA 14mg This product: 40mg UL 35mg

Sodium

55 mg (2% DV)

Lactobacillus acidophilus

Bifidobacterium longum

Fructooligosaccharides

30 mg

📊 Market median: 100.0mg (1 products) 📚 42 studies (Tier A: 1, B: 15)

This product: 30mg

Other Ingredients

Cellulose Rice Flour

Label Claims — Verification

❓ All Other

❓ Structure/Function

All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Suggested use: Take 1 capsule 2-3 times daily, preferably with food, or as directed by a healthcare professional.

⚠️ Warnings & Precautions

Caution: Do not exceed recommended dose.

Pregnant and nursing mothers, children under the age of 18, and individuals with a known medical condition should consult a physician before taking this or any dietary supplement.

🧪 Formulation Notes

Advanced support for healthy kidney function Powerful, natural, synergistic formula Supports kidney detoxification & normal function

Additional Information

GMP Good Manufacturing Practice Consistent Quality Made in the USA Manufactured at an FDA Registered Facility

Product Details

UPC / SKU 0 86156 24747 6

DSLD Entry Date 2024-04-23

Product Type Other Combinations

Form Capsule

Brand Healthy Kidney

DSLD ID 311522

Data Updated 2026-04-11

Research Evidence

241 Research Sources

55 Avg Quality Score

113 Meta Analysis

75 Systematic Review

32 Rct

11 Clinical Trial

3 Other

3 Regulatory Source

1 Cochrane Review

1 Narrative Review

1 Openfda Safety

A Niacin for primary and secondary prevention of cardiovascular events

Meta Analysis The Cochrane database of systematic reviews 2017

PubMed DOI Cochrane

A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases

Meta Analysis BMJ (Clinical research ed.) 2013

PubMed DOI

A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients

Meta Analysis BMJ (Clinical research ed.) 2014

PubMed DOI

A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk

Meta Analysis Nature medicine 2024

PubMed DOI

A Meta-analysis and imputation refines the association of 15q25 with smoking quantity

Meta Analysis Nature genetics 2010

PubMed DOI

A Genome-wide meta-analyses identify multiple loci associated with smoking behavior

Meta Analysis Nature genetics 2010

PubMed DOI

A Antidepressants for smoking cessation

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI

A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne

Meta Analysis The Cochrane database of systematic reviews 2020

PubMed DOI Cochrane

B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis

Meta Analysis JAMA network open 2019

PubMed DOI

B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis

Meta Analysis JAMA 2016

PubMed DOI

View all evidence for Niacin →